Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level

Executive Summary

The agency says human drug review costs were less than $1 billion in fiscal year 2013, the first time that’s happened since FY 2010.


Related Content

FDA Budget Issues Creep Into Strategic Priorities
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Sequester Travel: Halved FDA Budget Limits Opportunities For Scientists, Impacts Senior Officials Too
Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts